• Long Palantir (PLTR): the speaker praised its results, though the stock fell about 5%; no price target was provided, so consider the pullback alongside valuation and risk.
• Alnylam (ALNY) near $160 is a cautiously positive value idea after a drop from roughly $240; monitor underlying revenue growth and pipeline progress, as the speaker gave no price target.
• The speaker said to short Tesla (TSLA) and short Micron (MU), but both calls lacked supporting analysis; Tesla was showing relative strength and Micron was rallying, making these higher-risk trades.
• Apple (AAPL) was viewed cautiously at about 34× earnings (or even the high-20s), given uncertainty over whether recent growth can persist.

Palantir Technologies (PLTR)

• The speaker said “Long Palantir” and described its quarter and numbers as amazing.
• The stock was down about 5% during the discussion, despite the positive reaction to its results.

Takeaways

• The speaker’s view was bullish on Palantir’s business results, but the transcript gives no price target or valuation analysis. The stock’s drop shows that strong results did not prevent a decline that day.

Tesla (TSLA)

• The speaker said “Short Tesla,” while also noting that Tesla had been the strongest performer among the large technology names.
• He was unsure what was driving that strength and speculated that the market might be anticipating a merger involving SpaceX and a broader “Musk Empire.”

Takeaways

• The stated position was bearish, but the speaker acknowledged Tesla’s relative strength. The possible SpaceX merger was presented as speculation, not a confirmed development.

Micron Technology (MU)

• The speaker said “Short Micron.”
• Later, he noted that Micron was catching a rally, without changing or explaining the short thesis.

Takeaways

• The short position was explicit, but the transcript provides no supporting company or valuation analysis. The rally is a reminder that the stock’s near-term movement was running against the stated position.

Alnylam Pharmaceuticals (ALNY)

• The stock was described as around $160, down from about $240 relatively recently. The speaker said he did not understand why the market had sold it off so sharply.
• He described Alnylam as profitable and estimated its enterprise value at roughly $20 billion. He characterized the valuation as about five times earnings, while clarifying that this was a rough comparison based on gross profit after cost of goods, not after all company costs.
• He noted that revenue growth had slowed, but said growth remained rapid when excluding an unusual collaboration-related item. He also pointed to the natural limit on drug growth as a company reaches the patients who need a treatment.
• The discussion covered several pipeline and marketed-drug products, including patisiran, Oxlumo, nedosiran, and a Huntington’s disease program. He described continued growth in patisiran and said the older drugs were performing in line.

Takeaways

• The speaker sounded value-oriented and cautiously positive despite the sharp share-price decline. The key points to monitor from his discussion are whether underlying revenue growth remains strong and how the pipeline develops; he gave no price target.

Neurocrine Biosciences (NBIX)

• The speaker said Neurocrine reported 12% growth and called it a “big quarter.”
• He praised Ingrezza as an excellent drug and said Crenessity was also selling well. He also noted the company’s acquisition of Vykat XR from Soleno.

Takeaways

• The comments were positive, focused on commercial performance and growth from multiple products. No valuation view or explicit recommendation was provided.

Apple (AAPL)

• The speaker said product revenue grew substantially, while services grew more slowly. He also noted declines in iPad and wearables.
• He cited about 12% revenue growth and said recent growth had been strong, while questioning whether it would persist.
• He described Apple’s financials as clean but said he would not pay 34 times earnings, or even a multiple in the high 20s, because he was uncertain about the growth outlook.
• He raised the possibility that consumers could move on from the iPhone or adopt a new device category, though he did not know what that alternative would be. He also noted a sharp increase in R&D spending.

Takeaways

• The view was cautious on valuation, despite acknowledging recent growth and strong financials. The speaker’s main concerns were the durability of growth and potential changes in consumer technology.

Shopify (SHOP)

• Shopify was down about 10% during the discussion.
• The speaker did not analyze its results or give a clear view on the stock.

Takeaways

• The transcript offers no investment thesis for Shopify. The share-price move alone does not establish whether the speaker viewed it as attractive or unattractive.

Hyperliquid (HYPE)

• The speaker said he was “pretty bullish” on Hyperliquid and mentioned making about $20,000 in a day trading it.
• He described it as a decentralized leverage platform and said its stock-trading product, which offers up to 10x leverage, was its most compelling feature.

Takeaways

• The speaker expressed a bullish view, particularly on the stock-trading product. The transcript does not provide a valuation framework or a longer-term investment case.

Intel (INTC)

• The speaker said Intel had probably found a bottom for now, but added that he was not sure.
• He said Intel had appeared unwilling to fall below $60 and compared its performance unfavorably with AMD.

Takeaways

• The view was tentatively constructive but uncertain. The $60 level was an observation about recent trading, not a stated price target.

Advanced Micro Devices (AMD)

• AMD was up about 5% during the discussion.
• The speaker remarked on how strongly AMD was outperforming Intel.

Takeaways

• The comments suggest positive relative performance versus Intel, but the speaker did not give a specific AMD recommendation or explain the move.

NVIDIA (NVDA)

• The speaker noted NVIDIA at about $208 and said his computing setup was largely driven by NVIDIA hardware.
• No investment view or valuation analysis was given.

Takeaways

• NVIDIA was mentioned as a market and technology reference, not as a specific recommendation.

SanDisk (SNDK)

• SanDisk was described as up slightly during the market discussion.
• No company-specific thesis was offered.

Takeaways

• The transcript provides no actionable view beyond the brief market update.

Bloom Energy (BE)

• Bloom was up about 10%. The speaker noted that the company’s first quarter was its major quarter.
• He did not discuss its results, valuation, or outlook.

Takeaways

• The mention was limited to a market move and seasonal context; it does not establish a bullish or bearish investment view.

Moderna (MRNA)

• Asked whether Moderna was a short, the speaker said he did not know.

Takeaways

• The speaker expressed no clear position. The transcript provides no supporting analysis for a short or long view.

Alphabet (GOOGL)

• Alphabet was mentioned as one of the few technology companies, along with Apple and Meta, that the speaker considered to have relatively clean financials.
• No stock-specific view or valuation was provided.

Takeaways

• This was a favorable comment about financial reporting, not an explicit investment recommendation.

Meta Platforms (META)

• Meta was also described as having relatively clean financials compared with many other technology companies.
• No valuation analysis or recommendation was given.

Takeaways

• The comment was limited to financial quality; the transcript does not provide a broader investment thesis.

Novartis (NVS)

• The speaker mentioned Novartis’s Leqvio and referred to roughly $1 billion in gross profits for the drug. He also said he receives a royalty related to it.

Takeaways

• The discussion was about the drug’s economics, not a recommendation on Novartis shares.

Regeneron Pharmaceuticals (REGN)

• Regeneron came up in a brief discussion of a Huntington’s disease treatment program.
• The speaker did not offer a view on Regeneron’s stock or the program’s investment potential.

Takeaways

• No actionable stock thesis was provided.

Amgen (AMGN)

• The speaker jokingly referred to Amgen as “Scamgen,” then said it was a good company.
• No valuation or specific investment recommendation followed.

Takeaways

• The overall comment about the company was favorable, but it was not supported by a detailed stock thesis.

Anthropic (Private company; no public ticker)

• Asked whether he would buy Anthropic stock, the speaker said the answer depended on the price: he would buy at $1, but not at a $10 trillion valuation.

Takeaways

• The point was that a company’s investment appeal depends on its valuation. No actual share price or recommendation was provided.

AI, Biotechnology, and Space-Based Computing

• The speaker questioned whether AI would meaningfully improve farming, saying the person making that claim needed to provide the evidence.
• He also heard the claim that future superintelligence computing would overwhelmingly be located in space, but called that view extreme rather than endorsing it.
• In discussing biotech, he noted that drug growth can slow as a company reaches the patients who need a treatment.

Takeaways

• The transcript raises themes in AI, biotech, and space computing but does not establish a specific investment opportunity in those areas. The biotech discussion particularly highlights the importance of assessing how much growth a drug can sustain as its eligible patient population becomes more fully served.